Abstracts tagged "gout"

Abstract Number: 170 • 2013 ACR/ARHP Annual Meeting
Association Of BMI, 8 SNPs Reported To Be Related To Gout Phenotype and Their Interaction In Gout Incidence In Framingham Heart Study
Jasvinder A. Singh^1,2, Ana Vazquez³, Richard Reynolds³, Vinodh Srinivasasainagendra⁴, S. Louis Bridges Jr.⁵ and David Allison³, ¹Rheumatology, Birmingham VA, Birmingham, AL, ²Department of Medicine, University of Alabama, Tuscaloosa, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of alabama at birmingham, birmingham, AL, ⁵Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: We aim to assess the association of 8 serum urate SNPs and BMI and their interactions with incident gout in a population-based cohort study. Methods:…
Abstract Number: 1194 • 2013 ACR/ARHP Annual Meeting
Enhanced IL-1β and IL-6 Production In Gout Patients Upon Stimulation With Mono Sodium Urate Crystals and Synergizing Agents Compared To Healthy Volunteers
Tania O. Crisan¹, Maartje Cleophas¹, Mihai G. Netea¹, Tim L. Jansen² and Leo A. Joosten³, ¹Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: Gout is an autoinflammatory disease characterized by the deposition of monosodium urate (MSU) crystals in the joints of hyperuricaemic patients and subsequent attacks of…
Abstract Number: 1193 • 2013 ACR/ARHP Annual Meeting
Target Tophus Size and Complete Response Rates In Patients Treated With Open-Label Pegloticase For Chronic Gout Refractory To Conventional Therapy
Robert T. Keenan¹, Nicola Dalbeth² and Herbert S. B. Baraf³, ¹Rheumatology, Duke University, Durham, NC, ²Medicine, University of Auckland, Auckland, New Zealand, ³Arthritis & Rheumatism Associates, PC, Wheaton, MD
Background/Purpose: Pegloticase, a methoxyPEG-conjugated mammalian recombinant uricase, has been approved in the US and EU for the treatment of chronic gout refractory to xanthine oxidase…
Abstract Number: 2661 • 2013 ACR/ARHP Annual Meeting
Physical Activity, Adiposity, and The Risk Of Gout In Women: The Nurses Health Study
Hyon Choi^1,2,3, Lindsay C Burns^4,5, Yuqing Zhang⁶, Sharan Rai¹ and Gary Curhan⁷, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁵Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, ⁶Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁷German Research Center for Environmental Health, Harvard Medical School, Boston, MA
Background/Purpose: There is a remarkable, increasing disease burden of gout and its associated cardiovascular (CV)-metabolic comorbidities in the US. While the benefits of physical exercise…
Abstract Number: 1195 • 2013 ACR/ARHP Annual Meeting
Sex Differences In Gout Evaluation and Management
Leslie R. Harrold¹, Carol Etzel², Allan Gibofsky³, Joel M. Kremer⁴, Michael H. Pillinger⁵, Kenneth G. Saag⁶, Naomi Schlesinger⁷, Robert Terkeltaub⁸, Vanessa Cox² and Jeffrey D. Greenberg⁹, ¹University of Massachusetts Medical School, Worcester, MA, ²CORRONA, Inc, Southborough, MA, ³Medicine and Public Health, Hospital for Special Surgery, New York, NY, ⁴Center for Rheumatology, Albany Medical College, Albany, NY, ⁵NYU School of Medicine, Division of Rheumatology, New York, NY, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, ⁸Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁹Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY
Background/Purpose: Little is known regarding the evaluation, characteristics and management of women with gout. To characterize potential gender differences, we therefore compared clinical manifestations and…
Abstract Number: 1173 • 2013 ACR/ARHP Annual Meeting
A Clinically Significant Interaction Between Furosemide and Allopurinol: Potential Implications for Clinical Practice
Lisa K. Stamp¹, Claudia Knake² and Andrew Bahn², ¹Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Physiology, University of Otago, Dunedin, New Zealand
Background/Purpose: The xanthine oxidase (XO) inhibitor allopurinol is the most commonly used urate lowering therapy in gout. Allopurinol is metabolized to oxypurinol, which is responsible…
Abstract Number: 1991 • 2013 ACR/ARHP Annual Meeting
Gout In Ambulatory Care Settings In The US: 1993-2009
Eswar Krishnan and Linjun Chen, Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Gouty arthritis (gout) is primarily cared for in ambulatory care settings. Yet, there are few nationally representative data on ambulatory health care utilization of…
Abstract Number: 1196 • 2013 ACR/ARHP Annual Meeting
Chronic Renal Injury Does Not Prevent Achievement Of Target Serum Uric Acid In Tophaceous Gout
Mireille Aujero¹, J. Steuart Richards², Carl A. Nunziato³, David D. Maron⁴ and Gail S. Kerr⁵, ¹Rheuamtology Section, Washington DC VA Medical Center and Georgetown University, Washington, DC, ²Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ³Rheumatology, Washington DC VA and Howard University, Howard University Hospital, Washington, DC, ⁴Research Department, Washington DC VA Medical Center, Washington, DC, ⁵Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC
Background/Purpose: ACR 2012 management guidelines for tophaceous gout (TG) recommend urate lowering therapies (ULT) to achieve a target serum uric acid (SUA) of < 6.0…
Abstract Number: 857 • 2013 ACR/ARHP Annual Meeting
Impact of Urate Lowering Therapy On Renal Disease Progression in Patients With Hyperuricemia
Gerald D. Levy¹, T. Craig Cheetham², Nazia Rashid³ and Fang Niu², ¹Int Med/Rheumatology, Southern California Permanente Medical Group, Downey, CA, ²Pharmacy Analytical Services, Kaiser Permanente, Downey, CA, ³Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA
Background/Purpose: The relationship between elevated serum Uric Acid [sUA] and progression of chronic kidney disease is well established.1-3 There are a several small studies on…
Abstract Number: 1992 • 2013 ACR/ARHP Annual Meeting
Trends In Outpatient Treatment Of Gout In The US: From 1993 To 2009
Eswar Krishnan and Linjun Chen, Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Gouty arthritis (gout) is primarily managed in the community by primary care providers. Relatively little is known about the treatment patterns as well as…
Abstract Number: 1174 • 2013 ACR/ARHP Annual Meeting
Impact Of Bariatric Surgery On Serum Urate Targets in People With Morbid Obesity and Diabetes: A Prospective Longitudinal Study
Nicola Dalbeth¹, Peggy Chen², Marie White³, Gregory Gamble⁴, Caran Barratt-Boyes², Peter J. Gow⁵ and Brandon Orr-Walker², ¹Medicine, University of Auckland, Auckland, New Zealand, ²Counties Manukau District Health Board, Auckland, New Zealand, ³CCRep, Auckland, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵Rheumatology Dept, Middlemore Hospital, Auckland, New Zealand
Background/Purpose: Weight loss leads to reduced serum urate (SU) in people with obesity. However, the clinical relevance of such reductions in SU are unknown. This…
Abstract Number: 858 • 2013 ACR/ARHP Annual Meeting
Monosodium Urate Crystal Induced Macrophage Inflammation Is Attenuated By Chondroitin Sulfate: Pre-Clinical Model For Gout Prophylaxis?
Eric W. Orlowsky¹, Thomas V. Stabler², Eulalia Montell³, Josep Verges³ and Virginia B. Kraus², ¹Divsion of Rheumatology, Dept of Internal Medicine, Duke University Medical Center, Durham, NC, ²Medicine/Rheumatology, Duke University Medical Center, Durham, NC, ³Pre-Clinical R&D Area, Pharma Science Division, Bioibérica, Barcelona, Spain
Background/Purpose: Gout is one of the most common forms of inflammatory arthritis and is characterized by acute episodes of joint pain. Monosodium urate (MSU) crystals…
Abstract Number: 1989 • 2013 ACR/ARHP Annual Meeting
Determinants Of Functional Disability In Patients With Gout: Longitudinal Analysis From a Multicentre Observational Study Of The Italian Society For Rheumatology
Carlo Alberto Scirè¹, Maria Manara¹, Greta Carrara¹, Marco A. Cimmino², Marcello Govoni³, Fausto Salaffi⁴, Leonardo Punzi⁵, Carlomaurizio Montecucco⁶, Marco Matucci-Cerinic⁷ and Giovanni Minisola⁸, ¹Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Ferrara, Italy, ⁴Rheumatology Unit - Polytechnic University of the Marche, Jesi, Italy, ⁵Department of Medicine - DIMED, University of Padova, Padova, Italy, ⁶Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁷Rheumatology, University of Florence, Azienda Ospedaliera Careggi, Florence, Italy, ⁸Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Italy
Background/Purpose: Gout is the most prevalent arthritis and significantly impacts on function. Beside the influence of concurrent comorbidities, identifying disease-related prognostic factors may help to…
Abstract Number: 1176 • 2013 ACR/ARHP Annual Meeting
Pharmacokinetics and Pharmacodynamics Of Pegloticase In Patients With End-Stage Renal Failure Receiving Hemodialysis
Anthony J. Bleyer¹, David E. Wright² and Alan Glicklich³, ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Savient Pharmaceuticals, Inc., San Diego, CA, ³Savient Pharmaceuticals, Inc., Bridgewater, NJ
Background/Purpose: Among the estimated 8.3 million adults in the US with gout, approximately 40% have coexistent chronic kidney disease (CKD).1,2 Further, the presence of gout…
Abstract Number: 861 • 2013 ACR/ARHP Annual Meeting
Many Gout Patients Treated By Rheumatologists Do Not Meet Established Treatment Goals Despite Long-Term Urate Lowering Therapy: Results Of a Gout Patient Encounter Survey
Max I. Hamburger¹, Michael H. Pillinger², Robert Sederman³ and Gary Fernandez⁴, ¹Rheumatology Associates, Melville, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY, ³C1 Consulting, LLC, Summit, NJ, ⁴Market Research, Savient Pharmaceuticals, Bridgewater, NJ
Background/Purpose: In Oct 2012, the ACR published guidelines for the management of gout. These guidelines recommend pharmacologic treatment that results in a sufficient lowering of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].